香港医务卫生局宣布,在11月17日于捷克举行的“国际人用药品注册技术协调会”(ICH)大会上,“中国香港”获通过成为该组织第20个监管机构成员 1。此次加入由香港药剂业及毒药管理局作为代表机构参与,标志着香港在药物研发及监管领域的水平已获得国际认可 1。
除新加入的香港外,ICH的其他成员还包括中国国家药品监督管理局,以及来自欧洲、瑞士、英国和美国等地的监管机构 1。为推动建设国际医疗创新枢纽,港府计划于12月成立新的药物及医疗器械监督管理中心(药械监管中心) 1。
Hong Kong has officially joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) as a regulatory member, becoming the twentieth authority to hold this status within the organization 1. The decision was ratified during an ICH assembly held in the Czech Republic on November 17, with the Hong Kong Pharmacy and Poisons Board serving as the representative body for China Hong Kong 1. This membership aligns Hong Kong with other prominent global regulators, including the National Medical Products Administration of China, as well as authorities from Europe, Switzerland, the United Kingdom, and the United States 1.
In response to this milestone, the local government announced plans to establish a new Drug and Medical Device Regulatory Centre in December 1. Officials stated that joining the ICH signifies international acknowledgment of Hong Kong’s standards in pharmaceutical research and regulation 1. The administration aims to leverage this status to further develop the city into an international hub for medical innovation 1.
评论
还没有评论,欢迎留下第一条。